12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
应用 | 稀释度 |
---|---|
ELISA | 1.221-5000 ng/ml |
Pertuzumab is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. It is the first-in-class of a kind of drug called a "HER dimerization inhibitor" — it inhibits the dimerization of HER2 with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation.
Immobilized human Her2 at 0.5 μg/ml (50μL/well) can bind to Pertuzumab with a linear range of 1.221 ng/ml to 5 μg/ml.